comprehensive -WSS

comprehensive

author：focus 2025-10-01 20:14:34 - browse：523

Illustration of a bear on a red arrow with a bull underneath pushing the arrow upward. -- biotech coverage from STAT — Adobe

This was supposed to be the year of the biotech comeback, when promising new medicines and high-dollar buyouts would reverse a sector-wide slump that dates back to 2021. Instead, biotech stocks have dramatically underperformed the broader market, and the year’s few green shoots are yet to grow into a turnaround.

The closely watched XBI biotech index has fallen more than 10% in 2023, while the S&P 500 rose about 13% in the same period. Privately held companies have struggled to raise new capital without taking a hit to their valuations, and biotech IPOs have been rare in number and inconsistent in return.

The problem, analysts and investors said, is that the generalist investors who steer trillions of dollars of capital have simply soured on biotech. The furor over novel weight loss medicines like Wegovy has largely been a Big Pharma phenomenon, and rising interest rates have steered fund managers away from risky biotech stocks. The sector has gone through boom and bust cycles in the past, and it’s difficult, if not impossible, to predict when the macro winds might change and make biotech as popular as it was in the early days of Covid-19.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： BioMarin wins approval for gene therapy to treat hemophilia A
Next article： Ascension's ugly legal battle over care for poor patients in Texas

focus

WSS

Merck to acquire Harpoon Therapeutics for $680 million

Montana youths win climate lawsuit against state for promoting fossil fuels

Physician assistants need a new name. Here's what it should be

Fauci's latest grilling in Congress: 9 hours, behind closed doors

Megan Rapinoe shares emotional post following US Women's World Cup exit

Stories you might have missed in 2023: health, science, medicine

hotspot

comprehensive

leisure time

Virginia high school admissions case could be legal follow

Hospitals are dialing back on venture capital investing

Over 800 arrested across France in 3rd night of riots after fatal police shooting of teen

Stories you might have missed in 2023: health, science, medicine

Novavax promises a turnaround & Lilly roils the obesity market

STAT Virtual Event: JPM Recap, Live!

After affirmative action ruling, medical educators look to 'holistic review'

JPM 2024: Biotech’s most prolific dealmaker sees a rosy 2024

Indiana Supreme Court upholds abortion ban, says state constitution gives only limited protections

Biden administration begins canceling student loan debt for 804,000 borrowers

explore

Novo Nordisk touts Wegovy study, but still struggling with supply

Profiling embryos to choose those with higher IQs is almost a reality

Aspartame and sugar

Merck to acquire Harpoon Therapeutics for $680 million

Gene therapy denied for Afghan refugee whose father aided U.S.

Timeline: How the deadly wildfires took over Maui day by day

focus

focus

hotspot

explore